{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"37.9","value":"16.7"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"58.3","value":"26.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time interval from treatment initiation to date of first event (relapsed or progressive disease based on imaging or clinical progression or death from any cause) or to the date of last follow-up for patients without events. PFS was estimated using the method of Kaplan and Meier. The 1-year estimate of PFS is reported with a 95% confidence interval. PFS estimates were reported separately by dose level. Stratum 2 patients were those with newly diagnosed diffuse intrinsic pontine glioma (DIPG).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 2, Dose Level 3"}],"paramType":"NUMBER","populationDescription":"Newly diagnosed DIPG patients who were enrolled on Stratum 2 and received at least one dose of APX005M are included in this analysis.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Progression-free Survival for Stratum 2 (DIPG) Patients","type":"SECONDARY","unitOfMeasure":"Percent probability"}